Repositorio Institucional Fleni
Not a member yet
602 research outputs found
Sort by
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy
No full textBackground: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.
Methods: Exploratory analysis of the international NAVIGATE ESUS randomized trial comparing rivaroxaban 15mg daily with aspirin 100mg daily in 7213 patients with recent ESUS. Among participants with results of intracranial arterial imaging with either computed tomographic angiography (CTA) or magnetic resonance angiography (MRA), the frequency and predictors of non-stenotic intracranial and systemic atherosclerosis and responses to antithrombotic therapy were assessed.
Results: Among 4723 participants with available intracranial CTA or MRA results (65% of the trial cohort), the prevalence of intracranial atherosclerosis was 16% (n=739). Patient features independently associated with intracranial atherosclerosis included East Asian region (odds ratio 2.7, 95%CI 2.2,3.3) and cervical carotid plaque (odds ratio 2.3, 95%CI 1.9,2.7), among others. The rate of recurrent ischemic stroke averaged 4.8%/year among those with intracranial atherosclerosis vs. 5.0.%/year for those without (HR 0.95, 95%CI 0.65, 1.4). Among those with intracranial atherosclerosis, the recurrent ischemic stroke rate was higher if assigned to rivaroxaban (5.8%/year) vs. aspirin (3.7%/year), but the difference was not statistically significant (HR 1.6, 95%CI 0.78, 3.3). There was trend for the effect of antithrombotic treatments to be different according to the presence or absence of intracranial atherosclerosis (pinteraction=0.09). Among participants with evidence of systemic atherosclerosis by either history or imaging (n=3820), recurrent ischemic stroke rates were similar among those assigned to rivaroxaban (5.5%/year) vs. aspirin (4.9%/year)(HR 1.1, 95%CI 0.84, 1.5).
Conclusions: East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.Fil: Ameriso, Sebastián Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina.Fil: Mundl, Hardi. Bayer; Alemania.Fil: Hart, Robert G. Population Health Research Institute; Canadá.Fil: Amarenco, Pierre. Bichat Hospital. Department of Neurology; Francia.Fil: Pearce, Lesly A. Biostatistics Consultant; Estados Unidos.Fil: Perera, Kanjana S. McMaster University/Population Health Research Institute. Department of Medicine (Neurology); Canadá.Fil: Ntaios, George. University of Thessaly. Department of Medicine; Grecia.Fil: Lang, Wilfried. Sigmund Freud Private University. Hospital St. John of God. Medical Faculty; Austria.Fil: Bereczki, Daniel. Semmelweis University. Department of Neurology; Hungría.Fil: Uchiyama, Shinichiro. Sanno Hospital and Sanno Medical Center. International University of Health and Welfare; Japón.Fil: Kasner, Scott E. University of Pennsylvania. Department of Neurology; Estados Unidos.Fil: Yoon, Byung-Woo. Seoul National University Hospital. Department of Neurology; Corea.Fil: Lavados, Pablo M. Universidad del Desarrollo. Clinica Alemana de Santiago; Chile
.Fil: Firstenfeld, Alfredo. Instituto Cardiologico Banfield; Argentina.Fil: Mikulik, Robert. St. Anne's University Hospital and Masaryk University. International Clinical Research Center and Neurology Department; República Checa.Fil: Povedano, Guillermo Pablo. Complejo Medico de la PFA Churruca Visca; Argentina.Fil: Ferrari, Jorge. Hospital Interzonal General de Agudos Eva Peron; Argentina.Fil: Berkowitz, Scott D. Bayer. Pharmaceuticals Clinical Development Thrombosis; Estados Unidos.Fil: Connolly, Stuart J. McMaster University / Population Health Research Institute. Department of Medicine (Cardiology); Canadá
A look back into a typical patient with memory complains
No full textThe purpose of these images is to extol the biological perspective from the clinical setting perspective of a typical AD case. This participant was profoundly studied and also followed-up for five years in the study ADNI- ArgentinaFil: Chrem Méndez, Patricio Alexis. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría. Centro de Memoria y Envejecimiento; Argentina.Fil: Vázquez, Silvia. Fleni. Departamento de Neurología; Argentina
The sellar barrier on preoperative imaging predicts intraoperative cerebrospinal fluid leak: a prospective multicenter cohort study
No full textBackground: The type of sellar barrier observed between a pituitary tumor and cerebrospinal fluid (CSF) on preoperative magnetic resonance imaging (MRI) may predict intraoperative CSF leak during endonasal pituitary surgery. This is the first multicentric prospective cohort trial to study the sellar barrier concept and CSF leak rate during endoscopic pituitary surgery.
Methods: This multi-center, international study enrolled patients operated for pituitary adenomas via fully endoscopic endonasal surgery over a period of 4 months. The independent variable was the subtype of sellar barrier observed on preoperative MRI (strong, mixed or weak); the dependent variable was the presence of an intraoperative CSF leak. The primary goal was to determine the association between a particular type of sellar barrier and the risk of intraoperative CSF leak. Appropriate statistical methods were then applied for data analysis.
Results: Over the study period, 310 patients underwent endoscopic endonasal surgery for pituitary tumor. Preoperative imaging revealed a weak sellar barrier in 73 (23.55%), a mixed sellar barrier in 75 (24.19%), and a strong sellar barrier in 162 (52.26%) patients. The overall rate of intraoperative CSF leak among all patients was 69 (22.26%). A strong sellar-type barrier was associated with significantly reduced rate of intraoperative CSF leak (RR = 0.08; 95% CI 0.03-0.19; p < 0.0001), while a weak sellar barrier associated with higher rates of CSF leak (RR = 8.54; 95% CI 5.4-13.5; p < 0.0001).
Conclusions: The preoperative MRI of pituitary patients can suggest intraoperative CSF leak rates, utilizing the concept of the sellar barrier. Patients with a weak sellar barrier carry a higher risk for an intraoperative CSF leak, whereas a strong sellar barrier on MRI seems to mitigate intraoperative CSF leak. We propose that preoperatively assessment of the sellar barrier can prepare surgeons for intraoperative CSF leak repair.Fil: Cervio, Andrés Eduardo. Fleni. Departamento de Neurocirugía; Argentina.Fil: Villalonga, Juan Francisco. Universidad Nacional de Tucumán. Facultad de Medicina; Argentina.Fil: Solari, Domenico. Università degli Studi di Napoli Federico II. Department of Neurosciences, Reproductive and Odontostomatological Sciences. Division of Neurosurgery: Italia.Fil: Cavallo, Luigi M. Università degli Studi di Napoli Federico II. Department of Neurosciences, Reproductive and Odontostomatological Sciences. Division of Neurosurgery: Italia.Fil: Cappabianca, P. Università degli Studi di Napoli Federico II. Department of Neurosciences, Reproductive and Odontostomatological Sciences. Division of Neurosurgery: Italia.Fil: Prevedello, Daniel M.The Ohio State University. Wexner Medical Center. Department of Neurological Surgery; Estados Unidos.Fil: Carrau, Ricardo.The Ohio State University. Wexner Medical Center. Department of Neurological Surgery; Estados Unidos.Fil: Martínez Pérez, Rafael.The Ohio State University. Wexner Medical Center. Department of Neurological Surgery; Estados Unidos.Fil: Hardesty, Douglas.The Ohio State University. Wexner Medical Center. Department of Neurological Surgery; Estados Unidos.Fil: Fuchssteiner, Christoph. Medical University of Vienna. Center for Anatomy and Cell Biology. Division of Anatomy; Austria.Fil: Saenz, Amparo. Universidad Nacional de Tucumán. Facultad de Medicina; Argentina.Fil: Abbritti, Rosaria Viola. Lariboisière University Hospital Assistance Publique; Francia.Fil: Valencia Ramos, Cristopher. Instituto Nacional de Neurología y Neurocirugía; México.Fil: Kaen, Ariel. Hospital Virgen del Rocío; España.Fil: Bernat, Anne-Laure. Lariboisière University Hospital Assistance Publique; Francia.Fil: Cardenas, Eugenio. Hospital Virgen del Rocío; España.Fil: Hirtler, Lena. Medical University of Vienna. Center for Anatomy and Cell Biology. Division of Anatomy; Austria.Fil: Gómez Amador, Juan Luis. Instituto Nacional de Neurología y Neurocirugía; México.Fil: Liu, James. Rutgers New Jersey Medical School; Estados Unidos.Fil: Froelich, Sebastien. Lariboisière University Hospital Assistance Publique; Francia.Fil: Campero, Álvaro. Universidad Nacional de Tucumán. Facultad de Medicina; Argentina
Heart rate variability and falls in Huntington's disease
No full textPurpose: Persons with Huntington's disease (HD) have a high incidence of falls. Autonomic nervous system dysfunction has been reported even in early stages of this disease. To date, there has been no analysis of the relationship between heart rate variability (HRV) and falls in this patient population. The aim of the study reported here was to evaluate the relationship between HRV and falls in persons with HD.
Methods: Huntington's disease patients enrolled in a prospective study on fear of falling and falls were assessed using short-term HRV analyses and blood pressure measures in both the resting and standing states. Time-frequency domains and nonlinear parameters were calculated. Data on falls, the risk of falling (RoF) and disease-specific scales were collected at baseline and at the end of the 6-month follow-up.
Results: Of the 24 HD patients who were invited to participate in the study, 20 completed the baseline analysis and 18 completed the 6-month follow-up. At baseline, seven (35%) HD patients reported at least one fall (single fallers) and 13 (65%) reported ≥ 2 falls (recurrent fallers) in the previous 12 months. At baseline, recurrent fallers had lower RMSSD (root mean square of successive RR interval differences) in the resting state (RMSSD-resting), higher LF/HF (low/high frequency) ratio in both states and higher DFA-α1 parameter (detrended fluctuation analyses over the short term) in both states. This association was similar at the 6-month follow-up for recurrent fallers, who showed lower RMSSD-resting and higher LF/HF ratio in the standing state (LF/HF-standing) than single fallers. Significant correlations were found between the number of falls, RMSSD-resting and LF/HF-standing. No differences were found between recurrent and single fallers for any blood pressure measures.
Conclusions: The observed HRV pattern is consistent with a higher sympathetic prevalence associated with a higher RoF. Reduced parasympathetic HRV values in this patient population predict being a recurrent faller at 6 months of follow-up, independently of orthostatic phenomena.Fil: Merello, Marcelo. Fleni. Departamento de Neurología. Servicio de Movimientos Anormales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Fil: Terroba Chambi, Cinthia. Fleni. Departamento de Neurología. Servicio de Movimientos Anormales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Fil: Bruno, Verónica. University of Calgary. Department of Neurosciences; Canada.Fil: Vigo, Daniel Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontifical Catholic University of Argentina. Institute for Biomedical Research; Argentina.Katholieke Universiteit Leuven. Faculty of Psychology and Educational Sciences; Bélgica
Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: evidence from experimental models and Alzheimer's disease patients
No full textAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the presence of misfolded proteins, amyloid-β (Aβ) aggregates, and neuroinflammation in the brain. Microglial cells are key players in the context of AD, being capable of releasing cytokines in response to Aβ and degrading aggregated proteins by mechanisms involving the ubiquitin-proteasome system and autophagy. Here, we present in vivo and in vitro evidence showing that microglial autophagy is affected during AD progression. PDAPPJ20 mice-murine model of AD-exhibited an accumulation of the autophagy receptor p62 and ubiquitin+ aggregates in Iba1+ microglial cells close to amyloid deposits in the hippocampus. Moreover, cultured microglial BV-2 cells showed an enhanced autophagic flux during a 2-h exposure to fibrillar Aβ, which was decreased if the exposure was prolonged to 24 h, a condition analogous to the chronic exposure to Aβ in the human pathology. The autophagic impairment was also associated with lysosomal damage, depicted by membrane permeabilization as shown by the presence of the acid hydrolase cathepsin-D in cytoplasm and altered LysoTracker staining. These results are compatible with microglial exhaustion caused by pro-inflammatory conditions and persistent exposure to aggregated Aβ peptides. In addition, we found LC3-positive autophagic vesicles accumulated in phagocytic CD68+ microglia in human AD brain samples, suggesting defective autophagy in microglia of AD brain. Our results indicate that the capacity of microglia to degrade Aβ and potentially other proteins through autophagy may be negatively affected as the disease progresses. Preserving autophagy in microglia thus emerges as a promising approach for treating AD. Graphical abstract.Fil: Sevlever, Gustavo Emilio. Fleni. Departamento de Neuropatología y Biología Molecular; Argentina.Fil: Riudavets, Miguel. Fleni. Departamento de Neuropatología y Biología Molecular; Argentina.Fil: Pomilio, Carlos. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Gorojod, Roxana M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina.Fil: Vinuesa, Angeles. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Presa, Jessica. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Gregosa, Amal. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Bentivegna, Melisa. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Alaimo, Agustina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires y Consejo Nacional de Investigaciones Científicas y Técnicas. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina.Fil: Porte Alcon, Soledad. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina.Fil: Kotler, Monica L. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina.Fil: Beauquis, Juan. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina.Fil: Saravia, Flavia. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Universidad de Buenos Aires. Instituto de Biología y Medicina Experimental; Argentina
Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what"…
No full textNeurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer's disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us "where" abnormal tissue is found but not "what" molecular mechanisms are involved.Fil: Allegri, Ricardo Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina
Usage trend of oral drugs for multiple sclerosis patients in Argentina
No full textIntroduction: Over the past decade, numerous disease modifying drugs (DMDs) for relapsing- remitting multiple sclerosis (RRMS) have been approved in Argentina. The use of oral DMDs (oDMDs) has increased in recent years, although real-life data in our region is limited. We aimed to describe the tendency in the use of oDMDs (as first treatment option or after switch) in relationship with their approval in Argentina.
Methods: A retrospective study in a cohort of MS patients from five Argentinian MS centers was conducted. Regarding the availability of different oDMDs in Argentina, we define three periods (P1-3): P1: 2012 - 2014; P2: 2015 - 2017 and P3: 2018 - 2020. An analysis was performed comparing between these three periods to assess the tendency for oDMDs use over time.
Result: The most frequently prescribed treatment as first DMD was: interferon beta 1a (40%) in P1, fingolimod (37.3%) in P2 and also fingolimod (35%) in P3. We found an increase in the use of oDMTs as initial treatment over time (P1: 17.7%, P2: 63.9% and P3: 65.0%; Chi-square = 41.9 p <0.01). We also found a tendency to increase the use of oDMTs after a first switch (P1: 45.5%, P2: 60.1% and P3 78.3%). Multivariate analysis showed that disease evolution (OR=1.06, p=0.04), and year of treatment initiation (OR=1.01 p<0.01) were independently associated with choice of oDMTs.
Conclusion: This study identified an increasing tendency for the use of oDMDs as initial treatment of RMS in relationship with their approval in Argentina.Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Alonso, Ricardo. Hospital JM Ramos Mejía. Centro Universitario de Esclerosis Múltiple; Argentina. Sanatorio Güemes. Servicio de Neurología; Argentina.Fil: Garcea, Orlando. Hospital JM Ramos Mejía. Centro Universitario de Esclerosis Múltiple; Argentina.Fil: Eizaguirre, María Barbara. Hospital JM Ramos Mejía. Centro Universitario de Esclerosis Múltiple; Argentina.Fil: Man, Federico. Hospital Ramos Mejía. Servicio de Neurología; Argentina.Fil: Lopez Bizzo, Abril. Hospital Ramos Mejía. Servicio de Neurología; Argentina.Fil: Cohen, Leila. Hospital JM Ramos Mejía. Centro Universitario de Esclerosis Múltiple; Argentina.Fil: Rojas, Juan I. Centro de esclerosis múltiple de Buenos Aires; Argentina.Fil: Patrucco, Liliana. Centro de esclerosis múltiple de Buenos Aires; Argentina.Fil: Cristiano, Edgardo. Centro de esclerosis múltiple de Buenos Aires; Argentina.Fil: Pita, Cecilia. Hospital JM Ramos Mejía. Centro Universitario de Esclerosis Múltiple; Argentina.Fil: Tkachuk, Verónica. Hospital de Clínicas José de San Martín. Servicio de Neurología. Sección de Esclerosis Múltiple y Enfermedades Desmielinizantes; Argentina.Fil: Balbuena Aguirre, María Eugenia. Hospital de Clínicas José de San Martín. Servicio de Neurología. Sección de Esclerosis Múltiple y Enfermedades Desmielinizantes; Argentina.Fil: Carnero Contentti, Edgar. Hospital Alemán. Department of Neuroscience. Neuroimmunology Unit; Argentina.Fil: Lopez, Pablo. Hospital Alemán. Department of Neuroscience. Neuroimmunology Unit; Argentina.Fil: Pettinichi, Juan Pablo. Hospital Alemán. Department of Neuroscience. Neuroimmunology Unit; Argentina.Fil: Deri, Norma. Centro de Investigaciones Diabaid; Argentina.Fil: Miguez, Jimena. Hospital Italiano de Buenos Aires. Servicio de Neurología; Argentina.Fil: Pappolla, Agustín. Hospital Italiano de Buenos Aires. Servicio de Neurología; Argentina.Fil: Lazaro, Luciana. Sanatorio Güemes. Servicio de Neurología; Argentina
Full Femoral Osteomyelitis Caused by Fusobacterium nucleatum in an Immunocompetent Adult: A Case Report
No full textCase: We present a 46-year-old man who developed a full femoral osteomyelitis caused by Fusobacterium nucleatum. The subtle presentation of the infection and the late onset of appropriate antibiotic treatment caused a devastating bone quality of the full femur.
Conclusions: A successful outcome was obtained with surgical debridement, antibiotics, and return to weight bearing guided by a laboratory and radiographic scale specially designed to avoid pathologic fractures toward his full functional recovery.Fil: Rubel, Iván F. Fleni. Servicio de Neuroortopedia; Argentina.Fil: Reino, Fabricio M. Fleni. Departamento de Medicina Interna; Argentina
Hand bone conduction sound study by using the DSP Logger MX 300
No full textBone conduction is the transmission of acoustic energy to the inner ear by different paths involving the bones of the skull. In this work, we use the path the hand provides in order to transmit the sound coming from the cell phone using Bluetooth system. The aim of this work was to study the vibrations produced by a sound transmitted through bone conduction between a mobile phone and the hand analyzed with the DSP Logger MX equipment.Fil: Adler, Melanie Victoria. Instituto Tecnológico de Buenos Aires; Argentina.Fil: Fialá Sánchez, Mariana. Instituto Tecnológico de Buenos Aires; Argentina.Fil: Martini, Constanza. Instituto Tecnológico de Buenos Aires; Argentina.Fil: Vartabedian, Luciana Mariam. Instituto Tecnológico de Buenos Aires; Argentina.Fil: Zazzali, Matías Nicolás. Instituto Tecnológico de Buenos Aires; Argentina.Fil: Quintero-Rincón, Antonio. Fleni; Argentina
Mechanical thrombectomy for reperfusion of acute ischemic stroke in a Stroke Unit in Argentina
No full textObjective: Stroke is an important cause of morbidity and mortality worldwide. Reperfusion therapy with intravenous tissue plasminogen activator (IV-tPA) was first implemented in 1996. More recently, endovascular reperfusion with mechanical thrombectomy (MT) demonstrated a robust beneficial effect, extending the 4.5 h time window. In our country, there are difficulties to achieve the implementation of both procedures. Our purpose is to report the early experience of a Comprehensive Stroke Center in the use of MT for acute stroke.
Methods: Analysis of consecutive patients from January 2015 to September 2018, who received reperfusion treatment with MT. Demographic data, treatment times, previous use of IV-tPA, site of obstruction, recanalization, outcomes and disability after stroke were assessed.
Results: We admitted 891 patients with acute ischemic stroke during this period. Ninety-seven received IV-tPA (11%) and 27 were treated with MT (3%). In the MT group, mean age was 66.0±14.5 years. Median NIHSS before MT was 20 (range:14‒24). The most prevalent etiology was cardioembolic stroke (52%). Prior to MT, 16 of 27 patients (59%) received IV-tPA. Previous tPA treatment did not affect onset to recanalization time or door-to-puncture time. For MT, door-to-puncture time was 104±50 minutes and onset to recanalization was 289±153 minutes. Successful recanalization (mTICI grade 2b/3) was achieved in 21 patients (78%). At three-month follow-up, the median NIHSS was 5 (range:4‒15) and mRS was 0‒2 in 37%, and ≥3 in 63%.
Conclusions: With adequate logistics and strict selection criteria, MT can be implemented in our population with results like those reported in large clinical trials.Fil: Alet, Matías Javier. Fleni. Centro Integral de Neurología Vascular; Argentina.Fil: Rodríguez Lucci, Federico. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina.Fil: Ameriso, Sebastián Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina